Patent 7169901 was granted and assigned to Genentech on January, 2007 by the United States Patent and Trademark Office.
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.